ViroPharma

Results: 14



#Item
1reviews BOOKS • CD ROMS • ART • WEBSITES • MEDIA • PERSONAL VIEWS • SOUNDINGS SARS Reference Eds Bernd Sebastian Kamps,

reviews BOOKS • CD ROMS • ART • WEBSITES • MEDIA • PERSONAL VIEWS • SOUNDINGS SARS Reference Eds Bernd Sebastian Kamps,

Add to Reading List

Source URL: www.healthnewsreview.org

Language: English - Date: 2015-04-02 15:20:12
2reviews BOOKS • CD ROMS • ART • WEBSITES • MEDIA • PERSONAL VIEWS • SOUNDINGS SARS Reference Eds Bernd Sebastian Kamps,

reviews BOOKS • CD ROMS • ART • WEBSITES • MEDIA • PERSONAL VIEWS • SOUNDINGS SARS Reference Eds Bernd Sebastian Kamps,

Add to Reading List

Source URL: www.sarsreference.com

Language: English - Date: 2005-06-01 10:37:14
3Annual ReportOur journey forward At Shire we have a clear and focused strategy to become a leading global biotech delivering

Annual ReportOur journey forward At Shire we have a clear and focused strategy to become a leading global biotech delivering

Add to Reading List

Source URL: www.shire.com

Language: English - Date: 2015-03-26 07:09:24
4PRIOR AUTHORIZATION POLICY C1 esterase inhibitors Cinryze (C1 esterase inhibitor [human] for intravenous {IV} ViroPharma Biologics) Berinert® (C1 esterase inhibitor [human] for IV CSL Behring) Ruconest® (recombinant C1

PRIOR AUTHORIZATION POLICY C1 esterase inhibitors Cinryze (C1 esterase inhibitor [human] for intravenous {IV} ViroPharma Biologics) Berinert® (C1 esterase inhibitor [human] for IV CSL Behring) Ruconest® (recombinant C1

Add to Reading List

Source URL: statehealthplan.state.nc.us

Language: English - Date: 2014-11-24 08:41:11
5recurrent CDI Victoria for handout.ppt

recurrent CDI Victoria for handout.ppt

Add to Reading List

Source URL: novaclinical.com

Language: English - Date: 2014-11-05 12:32:20
6U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

Add to Reading List

Source URL: www.fda.gov

Language: English
7U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

Add to Reading List

Source URL: www.fda.gov

Language: English
8HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VANCOCIN CAPSULES safely and effectively. See full prescribing information for VANCOCIN CAPSULES. VANCOCIN® (vancom

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VANCOCIN CAPSULES safely and effectively. See full prescribing information for VANCOCIN CAPSULES. VANCOCIN® (vancom

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-12-14 16:25:38
9DRUG ALERT CLASS 2 MEDICINES RECALL Action Within 48 Hours Pharmacy, Dispensing Clinic and Wholesale Level Recall Date: 28 July 2014 EL (14)A/12

DRUG ALERT CLASS 2 MEDICINES RECALL Action Within 48 Hours Pharmacy, Dispensing Clinic and Wholesale Level Recall Date: 28 July 2014 EL (14)A/12

Add to Reading List

Source URL: www.mhra.gov.uk

Language: English - Date: 2014-07-28 07:21:31
    10ViroPharma Patent survey 2013 Table of Content Summary Objectives and methodology

    ViroPharma Patent survey 2013 Table of Content Summary Objectives and methodology

    Add to Reading List

    Source URL: www.knowmade.fr

    Language: English - Date: 2013-05-14 04:10:23